Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., executed a series of transactions on April 20, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is designed to satisfy affirmative defense conditions.
• The plan will continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• A total of 9,500 shares were acquired through option exercise at an average price of $146.03.
• Subsequently, various amounts of common stock were sold at weighted average prices ranging from $572.41 to $586.47.
• Following these transactions, Rothblatt beneficially owns 40,513 shares directly, with additional holdings indirectly through a spouse, trusts, and other arrangements.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the use of a compliant 10b5-1 plan.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating adherence to established compliance procedures for insider stock sales.
• The plan allows for continued option exercise and stock sales until a specified limit or date, providing flexibility for the reporting person.
• The weighted average prices for the sales indicate a significant gain compared to the option exercise price.

Negatives

• A substantial number of shares were sold by a key executive, which could be perceived negatively by the market.
• The total number of shares sold under this plan could be significant depending on the overall float and trading volume.

Risks

• The ongoing execution of the 10b5-1 plan means further sales may occur, potentially impacting share price if not absorbed by the market.
• The expiration of stock options on March 17, 2027, creates a timeframe for the plan's continuation and potential future exercises.

Future Outlook

The 10b5-1 trading plan is set to continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. These options expire on March 17, 2027.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various weighted average price transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, particularly those under 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. These plans are often used by executives to diversify holdings or manage personal finances in a compliant manner, but significant sales can still influence investor sentiment.

Stakeholder Impact

• Shareholders may view the sale of a significant number of shares by the CEO with caution, potentially impacting short-term stock price.
• Employees holding stock options may be influenced by the executive's decision to exercise and sell, though the 10b5-1 plan provides a compliant framework.

Next Steps

• Continued execution of the 10b5-1 trading plan until December 31, 2026, or until 1,734,410 stock options are exercised.
• Expiration of stock options on March 17, 2027.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established 10b5-1 plan. While the sale of a substantial number of shares by the CEO warrants attention, the compliant nature of the transaction and the lack of other negative financial or strategic information suggest a 'hold' recommendation pending further company developments.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, 10b5-1 Plan, United Therapeutics, UTHR, Martine Rothblatt, Common Stock, Beneficial Ownership